ClearPoint Neuro, Inc. Congratulates uniQure on Completion of Enrollment in First Cohort of Phase I/II Clinical Trial of AMT-130 for the Treatment of Huntington's Disease

Published Apr 06 2021 at 8:05 PM GMT
  • IRVINE, Calif., April 06, 2021 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc.
  • (NASDAQ:CLPT) (the "Company"), a global therapy-enabling platform company providing navigation and delivery to the brain, today congratulates uniQure NV on the early completion of patient enrollment in the first dose cohort of a randomized, double-blinded, Phase I/II clinical trial of AMT-130 being conducted in the United States for the treatment of early-stage Huntington's disease.
  • Six patients out of ten who were enrolled in the first cohort were randomized to receive AMT-130 gene therapy and underwent administration procedures using the ClearPoint® Neuro Navigation System and SmartFlow® MRI-safe neuro ventricular cannulae under MRI guidance.
  • The Company's clinical specialist team provided support during the administration and imitation surgery (sham) procedures to assist the study team in executing the clinical trial protocol.
  • A second, higher-dose cohort in this study is expected to begin enrolling 16 patients in the second half of 2021.


  • Published Apr 6, 2021 8:05 PM GMT